Poxel announced the appointment of Yves Decadt as Chief Executive Officer, effective June 10, 2026, as the company moves forward with the implementation of its Continuation Plan and seeks to accelerate the development and commercialization of its key assets.
Decadt succeeds Nicolas Trouche, whose leadership was focused on guiding the biopharmaceutical company through its restructuring process that began in August 2025. The transition had previously been scheduled for the first half of 2026 and follows the successful approval and execution of the Continuation Plan by the Lyon Commercial Court in January 2026.
The company said Decadt’s appointment reflects the strategic direction established by the new management team since the summer of 2025. He joined Poxel’s Board of Directors in October 2025 and has played a key role in defining the company’s commercial and strategic priorities.
As CEO, Decadt’s immediate priorities include accelerating partnership discussions for the commercialization of Imeglimin outside Japan, with a particular emphasis on China and other Asian markets, and advancing the development of PXL065 for hypertrophic cardiomyopathy (HCM) and metabolic dysfunction-associated steatohepatitis (MASH).
Decadt brings more than 25 years of experience in the pharmaceutical industry. He spent nearly two decades at Johnson & Johnson, where he specialized in international business development and licensing activities, particularly across Asia. He has also held senior leadership roles at several biopharmaceutical and medical technology companies.
Since August 2025, Decadt has worked closely with Poxel as a consultant, leading a strategic review of the company’s assets that helped shape the recovery plan presented to creditors and the court. He also oversaw the sale of PXL770 to Scynexis, a transaction designed to monetize the asset while freeing resources for the development of the company’s core programs.
Poxel’s portfolio includes Imeglimin, marketed in Japan as TWYMEEG by Sumitomo Pharma for the treatment of type 2 diabetes, and PXL065, a clinical-stage candidate being developed for HCM and MASH. The company continues to operate under the Continuation Plan approved earlier this year.
KEY QUOTES:
“Yves’ appointment as Chief Executive Officer is a logical step in strengthening our governance. His in-depth knowledge of our assets, acquired over the last ten months, combined with his international network and his experience in pharmaceutical business development in Asia, make him the best-placed leader to secure the partnerships that will enable Poxel to create value for all its stakeholders.”
Sophie Jacq Lapointe, Chairwoman of the Board of Directors, Poxel
“I am honoured to take the operational helm at Poxel at this pivotal moment. Our portfolio of assets holds significant commercial potential, particularly for Imeglimin, whose success in Japan demonstrates its clinical efficacy in type 2 diabetes. My immediate objective is to secure strategic partnerships that will accelerate the commercial development of our assets for the benefit of patients and our shareholders.”
Yves Decadt, Chief Executive Officer, Poxel
“I would like to thank all our stakeholders, shareholders, creditors, partners and employees, for their commitment and trust throughout this challenging period since the end of July 2025. Together with Yves, we have spent several weeks meticulously handing over all ongoing matters to ensure business continuity. I have every confidence in his ability to lead Poxel and ensure compliance with the Continuation Plan approved by the Lyon Commercial Court in January 2026.”
Nicolas Trouche, Outgoing Chief Executive Officer, Poxel
